8-K: Tharimmune Licenses Oral Infliximab Technology in Deal with Intract Pharma

Tharimmune has secured a global license to develop and commercialize an oral formulation of infliximab through a partnership with Intract Pharma.

Summary

• Tharimmune, Inc. has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-TNF monoclonal antibody infliximab.
• The agreement grants Tharimmune global development and commercialization rights (excluding South Korea) to Intract's Soteria and Phloral delivery platform.
• Tharimmune also gains access to an existing supply agreement for infliximab to be used in the oral product development program.
• Intract received an upfront payment and is eligible for additional payments upon an equity financing of Tharimmune.
• Intract is also eligible for future development, regulatory, and commercial milestone payments, as well as mid-single digit royalties on net product sales.
• Tharimmune retains a right of first refusal to continue development and commercialization after a Phase 2 clinical trial.
• Tharimmune has the option to license Intract's platform for up to four additional targets.
• The agreement can be terminated by Tharimmune with 90 days written notice or by either party for material breach or insolvency.
• The oral formulation of infliximab aims to improve patient compliance and reduce the burden on the healthcare system associated with intravenous therapy.
• The partnership leverages Intract's technology for targeted delivery of antibody therapeutics to the colon or small intestine.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic partnership and potential for a novel oral treatment, but there are risks associated with development and financing.

Positives

• Tharimmune gains access to a promising oral formulation of infliximab, potentially expanding its therapeutic pipeline.
• The partnership leverages Intract's innovative delivery platform, which could improve the effectiveness of TNFinhibitors.
• The oral route of administration has the potential to improve patient compliance and quality of life.
• The agreement includes a right of first refusal for Tharimmune to continue development after Phase 2, providing flexibility.
• The option to license Intract's platform for additional targets could lead to further pipeline expansion.

Negatives

• The agreement includes potential payments upon an equity financing of Tharimmune, which could dilute existing shareholders.
• The agreement includes milestone payments and royalties, which could impact future profitability.
• The agreement is subject to termination under certain conditions, including material breach or insolvency of either party.

Risks

• The development of an oral formulation of infliximab is complex and may face challenges.
• The success of the partnership depends on the effectiveness of Intract's delivery platform.
• The agreement is subject to termination under certain conditions, including material breach or insolvency of either party.
• The company may need to raise additional capital to fund the development of the oral infliximab.

Future Outlook

The company aims to advance the oral infliximab into clinical trials and potentially commercialize it, expanding its therapeutic focus and improving patient outcomes. The company may update the presentation in the future to reflect events and circumstances occurring or existing after the date of this Report, but specifically disclaims any obligation to do so.

Management Comments

• Randy Milby, CEO of Tharimmune, stated that the collaboration broadens their therapeutic focus and aligns with their mission to improve patient outcomes.
• Vipul Yadav, CEO of Intract, expressed delight in partnering with Tharimmune and bringing their clinical development expertise to advance the oral anti-TNF antibody.

Industry Context

This announcement reflects a growing trend in the pharmaceutical industry towards developing more convenient and patient-friendly drug delivery methods, particularly for biologics. The oral delivery of antibodies is a significant challenge, and this partnership aims to address this unmet need.

Comparison to Industry Standards

• The development of oral biologics is a key area of focus for many pharmaceutical companies, with several companies such as Rani Therapeutics and Oramed Pharmaceuticals working on similar technologies.
• The use of delivery platforms to enable oral administration of large molecules is a competitive space, with companies like Entera Bio and PureTech Health also developing their own proprietary technologies.
• The market for TNF-alpha inhibitors is dominated by injectable biologics like Remicade (infliximab), Humira (adalimumab), and Enbrel (etanercept), with the oral formulation representing a potential disruption to this market.
• The mid-single digit royalty rate is within the typical range for licensing agreements in the pharmaceutical industry, but the specific terms will depend on the stage of development and market potential of the product.

Stakeholder Impact

• Shareholders may see potential long-term value from the partnership, but may also experience dilution from potential equity financing.
• Patients with autoimmune diseases may benefit from a more convenient oral treatment option.
• Employees of Tharimmune may see new opportunities for growth and development.
• Intract Pharma will benefit from the upfront payment, milestone payments, and royalties.

Next Steps

• Tharimmune will proceed with the development of the oral infliximab.
• The company will file the agreement with its Form 10-Q for the quarter ended September 30, 2024.
• Tharimmune may exercise its option to license Intract's platform for additional targets.

Key Dates

Keywords

infliximab, oral formulation, monoclonal antibody, TNF-alpha, Intract Pharma, Tharimmune, licensing agreement, drug delivery, autoimmune diseases, immunology